Literature DB >> 20556833

Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma.

Jian-Jun Zhang1, He-Shui Wu, Lin Wang, Yuan Tian, Jing-Hui Zhang, Hai-Long Wu.   

Abstract

AIM: To investigate the expression of toll-like receptor (TLR) 4, nuclear factor-kappaB (NF-kappaB) p65 and hypoxia-inducible transcription factor 1alpha (HIF-1alpha) in pancreatic ductal adenocarcinoma and their clinical significance.
METHODS: The mRNA of TLR4 and HIF-1alpha were investigated by real-time polymerase chain reaction in 30 cases of pancreatic ductal adenocarcinoma and its adjacent tissues, and expression of TLR4, NF-kappaB p65 and HIF-1alpha protein were detected by immunohistochemistry in 65 cases of pancreatic ductal adenocarcinoma tissues and 38 cases of corresponding adjacent tissues. The relationship between TLR4 or HIF-1alpha and pathologic features, as well as the association between TLR4 and HIF-1alpha, were also analyzed. Kaplan-Meier method was used to assess the impact of expression of TLR4 and HIF-1alpha on survival of patients with pancreatic cancer.
RESULTS: The relative quantification of TLR4 and HIF-1alpha mRNA in tumor tissues was 0.81 +/- 0.10 and 0.87 +/- 0.11, respectively, significantly higher than that in adjacent tissues (0.81 +/- 0.10 vs 0.70 +/- 0.16, P = 0.002; 0.87 +/- 0.11 vs 0.68 +/- 0.13, P = 0.000). The protein expression of TLR4, NF-kappaB p65 and HIF-1alpha in tumor tissues was 69.20%, 66.15% and 70.80%, respectively, being significantly higher than that in adjacent normal tissues (69.20% vs 39.50%, P = 0.003; 66.15% vs 31.58%, P = 0.001; 70.80% vs 36.80%, P = 0.001). There was no significant correlation between TLR4 or HIF-1alpha expression and the age, gender, tumor location, the degree of tumor differentiation in the patients (P > 0.05). However, there was significant correlation between the expression of TLR4 or HIF-1alpha and tumor size, lymph node metastasis, venous invasion and clinical staging (P < 0.05). The expression of TLR4 and HIF-1alpha had a significant impact on survival of patients with pancreatic adenocarcinoma.
CONCLUSION: TLR4, NF-kappaB p65 and HIF-1alpha are overexpressed in pancreatic adenocarcinoma, TLR4 may be partly involved in up-regulating HIF-1alpha, and both synergestically promote development of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556833      PMCID: PMC2887583          DOI: 10.3748/wjg.v16.i23.2881

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

Review 3.  Hypoxia--a key regulatory factor in tumour growth.

Authors:  Adrian L Harris
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

4.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

5.  Toll-like receptor expression in normal ovary and ovarian tumors.

Authors:  Mingfu Zhou; Molly M McFarland-Mancini; Holly M Funk; Nader Husseinzadeh; Taofic Mounajjed; Angela F Drew
Journal:  Cancer Immunol Immunother       Date:  2009-01-31       Impact factor: 6.968

Review 6.  Hypoxia-inducible factor 1 (HIF-1) in cancer.

Authors:  M Quintero; N Mackenzie; P A Brennan
Journal:  Eur J Surg Oncol       Date:  2004-06       Impact factor: 4.424

7.  Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins.

Authors:  Hidenori Miyamoto; Tatsuya Murakami; Kunihiro Tsuchida; Hiromu Sugino; Hidenori Miyake; Seiki Tashiro
Journal:  Pancreas       Date:  2004-01       Impact factor: 3.327

Review 8.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

9.  Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha.

Authors:  Caroline C Blouin; Elisabeth L Pagé; Guylaine M Soucy; Darren E Richard
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

10.  The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease.

Authors:  G P Pidgeon; J H Harmey; E Kay; M Da Costa; H P Redmond; D J Bouchier-Hayes
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  40 in total

Review 1.  Role of TLR2-dependent inflammation in metastatic progression.

Authors:  Sunhwa Kim; Michael Karin
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  Microbiota, oral microbiome, and pancreatic cancer.

Authors:  Dominique S Michaud; Jacques Izard
Journal:  Cancer J       Date:  2014 May-Jun       Impact factor: 3.360

3.  High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.

Authors:  Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Petri Lehenkari; Juha Saarnio; Tuomo J Karttunen
Journal:  Virchows Arch       Date:  2017-02-12       Impact factor: 4.064

4.  Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.

Authors:  Lisa Volk-Draper; Kelly Hall; Caitlin Griggs; Sandeep Rajput; Pascaline Kohio; David DeNardo; Sophia Ran
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

Review 5.  HIF-1 at the crossroads of hypoxia, inflammation, and cancer.

Authors:  Kuppusamy Balamurugan
Journal:  Int J Cancer       Date:  2015-04-07       Impact factor: 7.396

6.  Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.

Authors:  Shipra Das; Beny Shapiro; Emily A Vucic; Sandra Vogt; Dafna Bar-Sagi
Journal:  Cancer Res       Date:  2020-01-08       Impact factor: 12.701

7.  Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.

Authors:  Daniel Delitto; Andrea E Delitto; Bayli B DiVita; Kien Pham; Song Han; Emily R Hartlage; Brittney N Newby; Michael H Gerber; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Thomas J George; Todd M Brusko; Clayton E Mathews; Chen Liu; Jose G Trevino; Steven J Hughes; Shannon M Wallet
Journal:  Cancer Res       Date:  2016-11-18       Impact factor: 12.701

8.  Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.

Authors:  Ling Zhou; Lianwen Qi; Lifeng Jiang; Ping Zhou; Jiang Ma; Xiaojun Xu; Ping Li
Journal:  AAPS J       Date:  2014-01-15       Impact factor: 4.009

Review 9.  Intervention on toll-like receptors in pancreatic cancer.

Authors:  Juan Vaz; Roland Andersson
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

10.  TLR4 is a novel determinant of the response to paclitaxel in breast cancer.

Authors:  Sandeep Rajput; Lisa D Volk-Draper; Sophia Ran
Journal:  Mol Cancer Ther       Date:  2013-05-29       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.